Boston Partners acquired a new position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 34,175 shares of the company's stock, valued at approximately $241,000. Boston Partners owned approximately 0.09% of Lifecore Biomedical at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LFCR. GAMMA Investing LLC raised its holdings in Lifecore Biomedical by 1,839.7% during the first quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock worth $25,000 after purchasing an additional 3,385 shares in the last quarter. Hurley Capital LLC acquired a new stake in Lifecore Biomedical during the first quarter worth approximately $35,000. Wells Fargo & Company MN increased its holdings in shares of Lifecore Biomedical by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock valued at $99,000 after acquiring an additional 3,012 shares during the period. MetLife Investment Management LLC acquired a new position in shares of Lifecore Biomedical in the 4th quarter valued at $108,000. Finally, XTX Topco Ltd acquired a new position in shares of Lifecore Biomedical in the 1st quarter valued at $145,000. Institutional investors and hedge funds own 83.36% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on LFCR shares. Wall Street Zen raised shares of Lifecore Biomedical from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. William Blair started coverage on shares of Lifecore Biomedical in a report on Wednesday, May 21st. They issued an "outperform" rating on the stock. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $8.00.
Check Out Our Latest Research Report on Lifecore Biomedical
Insiders Place Their Bets
In related news, major shareholder Aron R. English sold 1,139,504 shares of Lifecore Biomedical stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $6.50, for a total value of $7,406,776.00. Following the transaction, the insider directly owned 414,599 shares in the company, valued at $2,694,893.50. This trade represents a 73.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 32.20% of the stock is currently owned by company insiders.
Lifecore Biomedical Stock Performance
NASDAQ:LFCR traded up $0.38 during midday trading on Friday, reaching $7.60. The stock had a trading volume of 119,681 shares, compared to its average volume of 116,702. The firm has a fifty day simple moving average of $7.58 and a two-hundred day simple moving average of $6.81. Lifecore Biomedical, Inc. has a 12-month low of $3.68 and a 12-month high of $8.85. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76. The stock has a market cap of $284.32 million, a P/E ratio of -5.80 and a beta of 0.65.
Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. The firm had revenue of $36.44 million during the quarter, compared to analysts' expectations of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS. On average, equities analysts expect that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.
About Lifecore Biomedical
(
Free Report)
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
Further Reading
Before you consider Lifecore Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.
While Lifecore Biomedical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
